Morgan Stanley Revance Therapeutics, Inc. Transaction History

Morgan Stanley

$1.35 Trillion
Q3 2024

A detailed history of Morgan Stanley transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Morgan Stanley holds 867,127 shares of RVNC stock, worth $2.23 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

867,127

Previous 977,095 11.25%

Holding current value

$2.23 Million

Previous $2.51 Million 11.27%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$2.57 - $2.57 $282,617 - $282,617	-109,968 Reduced 11.25%	867,127 $2.23 Million
Q2 2024 Oct 17, 2024	SELL	$2.34 - $4.73 $530,733 - $1.07 Million	-226,809 Reduced 18.84%	977,095 $2.51 Million
Q2 2024 Aug 14, 2024	SELL	$2.34 - $4.73 $530,733 - $1.07 Million	-226,809 Reduced 18.84%	977,095 $2.51 Million
Q1 2024 Oct 17, 2024	BUY	$4.65 - $9.31 $1.05 Million - $2.11 Million	226,809 Added 23.21%	1,203,904 $5.92 Million
Q1 2024 Aug 16, 2024	BUY	$4.65 - $9.31 $1.51 Million - $3.02 Million	324,655 Added 36.92%	1,203,904 $5.92 Million
Q1 2024 May 15, 2024	BUY	$4.65 - $9.31 $1.51 Million - $3.02 Million	324,655 Added 36.92%	1,203,904 $5.92 Million
Q4 2023 Aug 16, 2024	SELL	$5.81 - $11.2 $568,485 - $1.1 Million	-97,846 Reduced 10.01%	879,249 $7.73 Million
Q4 2023 Feb 13, 2024	BUY	$5.81 - $11.2 $1.61 Million - $3.1 Million	277,054 Added 46.01%	879,249 $7.73 Million
Q3 2023 Nov 15, 2023	SELL	$11.47 - $25.07 $430,824 - $941,654	-37,561 Reduced 5.87%	602,195 $6.91 Million
Q2 2023 Aug 14, 2023	SELL	$24.7 - $37.61 $2.33 Million - $3.54 Million	-94,220 Reduced 12.84%	639,756 $16.2 Million
Q1 2023 May 15, 2023	SELL	$18.36 - $35.27 $1.19 Million - $2.29 Million	-64,820 Reduced 8.11%	733,976 $23.6 Million
Q4 2022 Feb 14, 2023	BUY	$18.32 - $30.66 $2.13 Million - $3.56 Million	116,091 Added 17.0%	798,796 $14.7 Million
Q3 2022 Nov 14, 2022	BUY	$14.33 - $28.47 $2.57 Million - $5.11 Million	179,621 Added 35.7%	682,705 $18.4 Million
Q2 2022 Oct 27, 2022	BUY	$11.52 - $20.4 $990,455 - $1.75 Million	85,977 Added 20.61%	503,084 $6.95 Million
Q2 2022 Aug 15, 2022	BUY	$11.52 - $20.4 $990,455 - $1.75 Million	85,977 Added 20.61%	503,084 $6.95 Million
Q1 2022 Oct 27, 2022	SELL	$12.36 - $20.31 $1.06 Million - $1.75 Million	-85,977 Reduced 17.09%	417,107 $8.13 Million
Q1 2022 May 13, 2022	BUY	$12.36 - $20.31 $593,527 - $975,286	48,020 Added 13.01%	417,107 $8.13 Million
Q4 2021 Feb 14, 2022	BUY	$12.46 - $27.87 $1.08 Million - $2.41 Million	86,477 Added 30.6%	369,087 $6.02 Million
Q3 2021 Nov 15, 2021	BUY	$25.78 - $33.21 $7.29 Million - $9.39 Million	282,610 New	282,610 $7.87 Million

Others Institutions Holding RVNC

# of Institutions

232

Shares Held

82.1M

Call Options Held

680K

Put Options Held

896K

View Full List

About Revance Therapeutics, Inc.

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

More about RVNC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account